EMA Reflection Paper on risk based Quality Management in Clinical Trials
The European Medicines Agency EMA has recently released a draft reflection paper on risk based quality management in clinical trials.
The purpose of this reflection paper is to facilitate the development of a more systematic, prioritised, risk-based approach to quality management of clinical trials, to support the principles of Good Clinical Practice and to complement existing quality practices, requirements and standards.
Please also see the reflection paper available for consultation for further details.
Comments related to this reflection paper should be provided using this template. The completed comments form should be sent to GCP@ema.europa.eu.
Please note that the deadline for comments for this reflection paper is 15 February 2012.
Related GMP News
07.10.2026FDA: Next Step to Reduce Animal Based Testing Methods
23.09.2026FDA Publishes Draft Guidance on Potency Testing of Active Immunotherapy Products
27.08.2026EMA publishes Consolidated ICH E6(R3) Guideline
28.07.2026WHO publishes GCP Guidelines for Comment
09.07.2026Final ICH E6(R3) Annex 2